Angiogenesis inhibitors in the treatment of lung cancer

Sophie Sun, Joan H. Schiller

Research output: Contribution to journalArticle

43 Scopus citations


Despite improvements in cytotoxic chemotherapy and combined modality therapies for lung cancer, the prognosis for patients remains poor, and the majority of patients die from the disease. Angiogenesis, i.e. the formation of new blood vessels, is important for tumor growth, invasion and metastasis and represents a rational target in the development of more effective treatments. The vascular endothelial growth factor (VEGF) signaling pathway plays a crucial role in the angiogenic process and consequently, inhibitors of this system are currently under development. The most studied anti-angiogenic agents include anti-VEGF monoclonal antibodies and VEGF receptor tyrosine kinase inhibitors. Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer.

Original languageEnglish (US)
Pages (from-to)93-104
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Issue number2
Publication statusPublished - May 2007



  • Angiogenesis inhibitors
  • Lung cancer
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this